サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1424050

皮下免疫グロブリン市場、シェア、規模、動向、産業分析レポート：最終用途別、地域別、セグメント別予測、2024-2032年

Subcutaneous Immunoglobulin Market Share, Size, Trends, Industry Analysis Report, By Application (Primary Immunodeficiency Disease, Secondary Immunodeficiency Disease); By End Use; By Region; Segment Forecast, 2024- 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
皮下免疫グロブリン市場、シェア、規模、動向、産業分析レポート：最終用途別、地域別、セグメント別予測、2024-2032年
出版日: 2024年01月24日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、皮下免疫グロブリンの世界市場規模は2032年までに330億2,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

皮下免疫グロブリン市場は、適応症の拡大と治療用途の拡大により、有利な機会を生み出しています。皮下免疫グロブリン製剤は、免疫不全症における従来の用途にとどまらず、自己免疫疾患、神経学、皮膚科学などの分野でも利用されつつあります。慢性炎症性脱髄性多発ニューロパチー（CIDP）、重症筋無力症、多巣性運動ニューロパチーのような疾患における免疫グロブリンの潜在的な有用性を示す調査が、採用拡大を後押ししています。皮下免疫グロブリン製剤の汎用性と患者に優しい投与方法は、多様な医療領域における有望な治療オプションとして位置付けられ、市場を多様化し、適応症と治療領域を拡大することで進化するヘルスケア状況に対応しています。

小児への適用は、皮下免疫グロブリン市場の機会を促進する上で極めて重要です。皮下免疫グロブリンは、小児の免疫不全症に対する有望な治療法として、侵襲性が低く利便性の高い選択肢を提供し、支持を集めています。皮下投与法は治療のアドヒアランスを高め、小児に優しいヘルスケアソリューションに対する需要の高まりに対応しています。小児集団に対する有効性と安全性に重点を置き、小児における免疫不全症の有病率の上昇に対応しています。

患者中心の医療、特に免疫不全症のような慢性疾患に対する動向が、在宅投与の需要を高めています。このアプローチは患者の快適性と利便性を高め、ヘルスケア施設の負担を軽減します。使いやすい輸液デバイスや患者・介護者向けの教育リソースが利用可能なことも、在宅投与をさらに後押ししています。ヘルスケアが分散型モデルへと進化し、患者が自分の治療をよりコントロールしたいと望む中、皮下免疫グロブリン市場は、医療提供の移り変わりを反映し、アクセスしやすく効果的な在宅ソリューションを提供することで成長しています。

製薬会社は、皮下免疫グロブリンの利便性とアクセスのしやすさから人気の高い治療法となっている発展途上地域をターゲットとするようになってきています。このような新興市場では、ヘルスケアのインフラが拡大し、先進的な治療法に対する認識が高まっているため、皮下免疫グロブリンの普及に適した環境が整っています。十分な治療を受けていない人々へのアプローチにより、同市場は効果的な免疫不全症治療を提供するという世界の目標に合致しています。これらの地域のヘルスケアシステムが進歩するにつれて、皮下免疫グロブリン市場は未開拓の可能性を活用し、革新的なソリューションを提供し、これらのダイナミックで拡大する市場での成長を促進する好位置につけています。

皮下免疫グロブリン市場レポートハイライト

2023年には、在宅投与、全身性副作用の軽減、患者満足度の向上により、原発性免疫不全症部門が大きな市場シェアを占めました。

2023年には、免疫不全疾患、神経疾患、自己免疫疾患への応用により、病院セグメントが大きな売上シェアを占めました。

2023年には、患者の意識の高まり、ヘルスケア支出の増加、患者中心の医療により、北米地域が世界市場を独占しました。

この市場は、Bio Product Laboratory、Biotest AG、CSL Behring、Grifols、Laboratoire francais du Fractionnement et des Biotechnologies、Octapharma、武田薬品工業など、世界的に存在感を示す市場参入企業が存在するため、競争が激しいです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の皮下免疫グロブリン市場に関する洞察

  • 皮下免疫グロブリン市場- 業界スナップショット
  • 皮下免疫グロブリン市場力学
    • 促進要因と機会
      • 免疫不全疾患の発生率の増加により、製品の需要が刺激されると予測されています
      • 患者中心のアプローチが市場の成長を促進すると予想される
    • 抑制要因と課題
      • 高額な治療費が市場の成長を妨げる可能性がある
  • PESTLE分析
  • 皮下免疫グロブリン業界の動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界の皮下免疫グロブリン市場、用途別

  • 主な調査結果
  • イントロダクション
  • 原発性免疫不全症
  • 続発性免疫不全症

第6章 世界の皮下免疫グロブリン市場、最終用途別

  • 主な調査結果
  • イントロダクション
  • クリニック
  • 病院
  • 在宅ケア
  • その他

第7章 世界の皮下免疫グロブリン市場、地域別

  • 主な調査結果
  • イントロダクション
    • 皮下免疫グロブリン市場評価、地域別、2019-2032年
  • 皮下免疫グロブリン市場-北米
    • 北米：皮下免疫グロブリン市場、最終用途別、2019-2032年
    • 北米：皮下免疫グロブリン市場、用途別、2019-2032年
    • 皮下免疫グロブリン市場-米国
    • 皮下免疫グロブリン市場- カナダ
  • 皮下免疫グロブリン市場- 欧州
    • 欧州：皮下免疫グロブリン市場、最終用途別、2019～2032年
    • 欧州：皮下免疫グロブリン市場、用途別、2019～2032年
    • 皮下免疫グロブリン市場- 英国
    • 皮下免疫グロブリン市場- フランス
    • 皮下免疫グロブリン市場- ドイツ
    • 皮下免疫グロブリン市場- イタリア
    • 皮下免疫グロブリン市場- スペイン
    • 皮下免疫グロブリン市場- オランダ
    • 皮下免疫グロブリン市場- ロシア
  • 皮下免疫グロブリン市場- アジア太平洋
    • アジア太平洋：皮下免疫グロブリン市場、最終用途別、2019～2032年
    • アジア太平洋：皮下免疫グロブリン市場、用途別、2019～2032年
    • 皮下免疫グロブリン市場- 中国
    • 皮下免疫グロブリン市場- インド
    • 皮下免疫グロブリン市場- マレーシア
    • 皮下免疫グロブリン市場- 日本
    • 皮下免疫グロブリン市場- インドネシア
    • 皮下免疫グロブリン市場- 韓国
  • 皮下免疫グロブリン市場-中東およびアフリカ
    • 中東およびアフリカ：皮下免疫グロブリン市場、最終用途別、2019～2032年
    • 中東およびアフリカ：皮下免疫グロブリン市場、用途別、2019～2032年
    • 皮下免疫グロブリン市場- サウジアラビア
    • 皮下免疫グロブリン市場- アラブ首長国連邦
    • 皮下免疫グロブリン市場- イスラエル
    • 皮下免疫グロブリン市場- 南アフリカ
  • 皮下免疫グロブリン市場-ラテンアメリカ
    • ラテンアメリカ：皮下免疫グロブリン市場、最終用途別、2019-2032年
    • ラテンアメリカ：皮下免疫グロブリン市場、用途別、2019-2032年
    • 皮下免疫グロブリン市場- メキシコ
    • 皮下免疫グロブリン市場- ブラジル
    • 皮下免疫グロブリン市場- アルゼンチン

第8章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • ADMA Biologics
  • Bio Product Laboratory
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Behring
  • Emergent BioSolutions
  • Grifols
  • Hansa Biopharma
  • InVivo Biotech Services
  • Kedrion Biopharma
  • Kamada Ltd.
  • Laboratoire francais du Fractionnement et des Biotechnologies
  • Octapharma
  • Shenzhen Weiguang Biological Products Co., Ltd.
  • Takeda Pharmaceutical Company
図表

List of Tables

  • Table 1 Global Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 2 Global Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 3 Subcutaneous Immunoglobulin Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 5 North America: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 6 U.S.: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 7 U.S.: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 8 Canada: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 9 Canada: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 10 Europe: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 11 Europe: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 12 UK: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 13 UK: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 14 France: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 15 France: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Germany: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 17 Germany: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 18 Italy: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 19 Italy: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 20 Spain: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 21 Spain: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 24 Russia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 25 Russia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 28 China: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 29 China: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 30 India: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 31 India: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 34 Japan: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 35 Japan: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 38 South Korea: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 39 South Korea: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 44 UAE: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 45 UAE: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 46 Israel: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 47 Israel: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 48 South Africa: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 49 South Africa: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 50 Latin America: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 51 Latin America: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Mexico: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 53 Mexico: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 54 Brazil: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 55 Brazil: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • Table 56 Argentina: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • Table 57 Argentina: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Subcutaneous Immunoglobulin Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by End Use
  • Figure 7 Global Subcutaneous Immunoglobulin Market, by End Use, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Application
  • Figure 9 Global Subcutaneous Immunoglobulin Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 10 Subcutaneous Immunoglobulin Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Subcutaneous Immunoglobulin Market
目次
Product Code: PM4416

The global Subcutaneous Immunoglobulin market size is expected to reach USD 33.02 billion by 2032, according to a new study by Polaris Market Research. The report "Subcutaneous Immunoglobulin Market Share, Size, Trends, Industry Analysis Report, By Application (Primary Immunodeficiency Disease, Secondary Immunodeficiency Disease); By End Use; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Expanded indications and therapeutic applications are creating lucrative opportunities in the subcutaneous immunoglobulin market. Beyond its traditional use in immunodeficiency disorders, it is gaining traction in autoimmune diseases, neurology, and dermatology. Research showcasing its potential benefits in conditions like chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, and multifocal motor neuropathy is driving increased adoption. The versatility and patient-friendly administration of subcutaneous immunoglobulin position it as a promising therapeutic option across diverse medical domains, diversifying the market and responding to the evolving healthcare landscape with expanded indications and therapeutic areas.

Pediatric applications are crucial in driving opportunities within the subcutaneous immunoglobulin market. Subcutaneous immunoglobulin is gaining traction as a promising treatment for immunodeficiency disorders in children, offering a less invasive and more convenient alternative. The subcutaneous administration method enhances treatment adherence, meeting the growing demand for child-friendly healthcare solutions. With a focus on efficacy and safety for the pediatric population, it addresses the rising prevalence of immunodeficiency disorders in children.

The trend towards patient-centric care, particularly for chronic conditions like immunodeficiency disorders, has intensified the demand for home-based administration. This approach enhances patient comfort and convenience and reduces the strain on healthcare facilities. The availability of user-friendly infusion devices and educational resources for patients and caregivers further supports home-based administration. As healthcare evolves towards decentralized models and patients desire more control over their treatment, the subcutaneous immunoglobulin market is growing by offering accessible and effective home-based solutions, reflecting the shifting landscape of healthcare delivery.

Pharmaceutical companies are increasingly targeting developing regions, where subcutaneous immunoglobulin's convenience and accessibility make it a sought-after treatment. Expanding healthcare infrastructure and growing awareness of advanced therapies in these emerging markets create a conducive environment for subcutaneous immunoglobulin adoption. By reaching underserved populations, the market aligns with the global goal of providing effective immunodeficiency disorder therapies. As healthcare systems in these regions advance, the subcutaneous immunoglobulin market is well-positioned to capitalize on the untapped potential, offering innovative solutions and fostering growth in these dynamic and expanding markets.

Subcutaneous Immunoglobulin Market Report Highlights

In 2023, the primary immunodeficiency disease segment accounted for significant market share owing to home-based administration, reduced systemic side effects, and improved patient satisfaction.

In 2023, the hospital segment held significant revenue share owing to application in immunodeficiency disorders, neurological conditions, and autoimmune disorders.

In 2023, North America region dominated the global market due to increasing patient awareness, rising healthcare expenditure, and patient-centric care.

The market is highly competitive owing to the existence of market players with a global presence, including Bio Product Laboratory, Biotest AG, CSL Behring, Grifols, Laboratoire francais du Fractionnement et des Biotechnologies, Octapharma, and Takeda Pharmaceutical Company among others.

Polaris Market Research has segmented the Subcutaneous Immunoglobulin market report based on application, end use, and region:

Subcutaneous Immunoglobulin, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Primary Immunodeficiency Disease
  • Secondary Immunodeficiency Disease

Subcutaneous Immunoglobulin, End Use Outlook (Revenue - USD Billion, 2019 - 2032)

  • Clinics
  • Hospitals
  • Homecare
  • Others

Subcutaneous Immunoglobulin, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Netherlands
  • Spain
  • Russia
  • Asia Pacific
  • Japan
  • China
  • India
  • Malaysia
  • Indonesia
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Subcutaneous Immunoglobulin Market Insights

  • 4.1. Subcutaneous Immunoglobulin Market - Industry Snapshot
  • 4.2. Subcutaneous Immunoglobulin Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing incidence of immunodeficiency disorders is projected to spur the product demand
      • 4.2.1.2. Patient-centric approach is expected to drive market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of treatment is likely to impede the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Subcutaneous Immunoglobulin Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Subcutaneous Immunoglobulin Market, by Application

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Subcutaneous Immunoglobulin, by Application, 2019-2032 (USD Billion)
  • 5.3. Primary Immunodeficiency Disease
    • 5.3.1. Global Subcutaneous Immunoglobulin Market, by Primary Immunodeficiency Disease, by Region, 2019-2032 (USD Billion)
  • 5.4. Secondary Immunodeficiency Disease
    • 5.4.1. Global Subcutaneous Immunoglobulin Market, by Secondary Immunodeficiency Disease, by Region, 2019-2032 (USD Billion)

6. Global Subcutaneous Immunoglobulin Market, by End Use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
  • 6.3. Clinics
    • 6.3.1. Global Subcutaneous Immunoglobulin Market, by Clinics, by Region, 2019-2032 (USD Billion)
  • 6.4. Hospitals
    • 6.4.1. Global Subcutaneous Immunoglobulin Market, by Hospitals, by Region, 2019-2032 (USD Billion)
  • 6.5. Homecare
    • 6.5.1. Global Subcutaneous Immunoglobulin Market, by Homecare, by Region, 2019-2032 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Subcutaneous Immunoglobulin Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Subcutaneous Immunoglobulin Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Subcutaneous Immunoglobulin Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Subcutaneous Immunoglobulin Market - North America
    • 7.3.1. North America: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
    • 7.3.2. North America: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.3.3. Subcutaneous Immunoglobulin Market - U.S.
      • 7.3.3.1. U.S.: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.3.4. Subcutaneous Immunoglobulin Market - Canada
      • 7.3.4.1. Canada: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 7.4. Subcutaneous Immunoglobulin Market - Europe
    • 7.4.1. Europe: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.3. Subcutaneous Immunoglobulin Market - UK
      • 7.4.3.1. UK: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.4. Subcutaneous Immunoglobulin Market - France
      • 7.4.4.1. France: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.5. Subcutaneous Immunoglobulin Market - Germany
      • 7.4.5.1. Germany: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.6. Subcutaneous Immunoglobulin Market - Italy
      • 7.4.6.1. Italy: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.7. Subcutaneous Immunoglobulin Market - Spain
      • 7.4.7.1. Spain: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.8. Subcutaneous Immunoglobulin Market - Netherlands
      • 7.4.8.1. Netherlands: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.4.9. Subcutaneous Immunoglobulin Market - Russia
      • 7.4.9.1. Russia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 7.5. Subcutaneous Immunoglobulin Market - Asia Pacific
    • 7.5.1. Asia Pacific: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.3. Subcutaneous Immunoglobulin Market - China
      • 7.5.3.1. China: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.4. Subcutaneous Immunoglobulin Market - India
      • 7.5.4.1. India: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.5. Subcutaneous Immunoglobulin Market - Malaysia
      • 7.5.5.1. Malaysia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.6. Subcutaneous Immunoglobulin Market - Japan
      • 7.5.6.1. Japan: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.7. Subcutaneous Immunoglobulin Market - Indonesia
      • 7.5.7.1. Indonesia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.5.8. Subcutaneous Immunoglobulin Market - South Korea
      • 7.5.8.1. South Korea: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 7.6. Subcutaneous Immunoglobulin Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.6.3. Subcutaneous Immunoglobulin Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.6.4. Subcutaneous Immunoglobulin Market - UAE
      • 7.6.4.1. UAE: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.6.5. Subcutaneous Immunoglobulin Market - Israel
      • 7.6.5.1. Israel: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.6.6. Subcutaneous Immunoglobulin Market - South Africa
      • 7.6.6.1. South Africa: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
  • 7.7. Subcutaneous Immunoglobulin Market - Latin America
    • 7.7.1. Latin America: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.7.3. Subcutaneous Immunoglobulin Market - Mexico
      • 7.7.3.1. Mexico: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.7.4. Subcutaneous Immunoglobulin Market - Brazil
      • 7.7.4.1. Brazil: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)
    • 7.7.5. Subcutaneous Immunoglobulin Market - Argentina
      • 7.7.5.1. Argentina: Subcutaneous Immunoglobulin Market, by End Use, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Subcutaneous Immunoglobulin Market, by Application, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. ADMA Biologics
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Bio Product Laboratory
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Biotest AG
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. China Biologic Products Holdings, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. CSL Behring
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6.Emergent BioSolutions
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Grifols
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Hansa Biopharma
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. InVivo Biotech Services
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Kedrion Biopharma
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Kamada Ltd.
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Laboratoire francais du Fractionnement et des Biotechnologies
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Octapharma
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Shenzhen Weiguang Biological Products Co., Ltd.
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Takeda Pharmaceutical Company
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development